Navigation Links
After a Stroke, When Seconds Count, Innovative Device from NeuroInterventions Speedily Restores Brain's Blood Flow
Date:10/11/2009

WASHINGTON, Oct. 11 /PRNewswire/ -- A new device from NeuroInterventions, Inc., is designed to minimize brain damage by dramatically speeding the delivery of post-stroke countermeasures.

"Stroke is the third most frequent cause of death, and the number-one cause of permanent disability," says NeuroInterventions President and COO Michele Migliuolo [mil-u-OLO]. "When a clot blocks the flow of oxygen-rich blood in the brain, the 'window' for surgical help is only a few hours wide. Every second can mean a drop in brain function."

So, driven by the emergency-room maxim, "Time is brain," NeuroInterventions has developed groundbreaking technology that enables surgeons to reach and remove clots in much less time than conventional approaches. Dr. Migliuolo will describe the development in a presentation today at AdvaMed 2009, at the Walter E. Washington Convention Center, Room 304, at 10:20 a.m.

"Even after a patient reaches a hospital, it can take up to 60 minutes just to introduce a conventional catheter through the femoral artery and steer it to the site, before you can deal with the clot," he says.

Capable of dissolving or extracting clots and delivering medication, the NeuroInterventions system takes a shorter, faster path to the brain. With exceptional maneuverability for negotiating the circulatory system, "Our devices will benefit patients, physicians, hospitals and insurance companies by improving outcomes through shorter, more effective treatment; by permitting more complex procedures; and by reducing recovery times."

Based in Pittsburgh, NeuroInterventions is prototyping a family of patent-pending catheters for addressing deep vein thrombosis, carotid stenting, and traumatic brain injury, in addition to stroke. The technology also facilitates localized drug and stem cell delivery.

On the management team are world leaders in interventional radiology, neurology and neurosurgery, as well as successful entrepreneurs, among them: Lawrence Wechsler, M.D., chair of the Department of Neurology and director of the Stroke Institute at the University of Pittsburgh Medical Center; Mark H. Wholey, M.D., founder and director of the Pittsburgh Vascular Institute; Tudor Jovin, M.D., co-director of the Center for Neuroendovascular Therapy at the University of Pittsburgh Medical Center; Ender Finol, Ph.D., associate research professor for the Institute for Complex Engineered Systems and Biomedical Engineering Department at Carnegie Mellon University; and Dr. Migliuolo, a high-tech entrepreneur and former executive in residence at the Pittsburgh Life Sciences Greenhouse.

    Media contact: Michele Migliuolo, Ph.D.
    info@neurointerventions.com
    412-663-0109

SOURCE NeuroInterventions, Inc.


'/>"/>
SOURCE NeuroInterventions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ekkyo Presents a Positive Assessment one Year After the Launch of EkkyLite(TM), its New Scar Healing System
2. New Reconstruction Method Makes Speaking, Eating Possible After Tonsil Cancer Surgery, U-M Study Shows
3. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
4. Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
5. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
6. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
7. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
8. Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
9. Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
10. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
11. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):